PL2032531T3 - Sole N-hydroksy-3-[4-[[[2-(2-metylo-1H-indol-3-ilo)etylo]amino]metylo]fenylo]-2E-2-propenoamidu - Google Patents

Sole N-hydroksy-3-[4-[[[2-(2-metylo-1H-indol-3-ilo)etylo]amino]metylo]fenylo]-2E-2-propenoamidu

Info

Publication number
PL2032531T3
PL2032531T3 PL07784348T PL07784348T PL2032531T3 PL 2032531 T3 PL2032531 T3 PL 2032531T3 PL 07784348 T PL07784348 T PL 07784348T PL 07784348 T PL07784348 T PL 07784348T PL 2032531 T3 PL2032531 T3 PL 2032531T3
Authority
PL
Poland
Prior art keywords
methyl
propenamide
indol
hydroxy
phenyl
Prior art date
Application number
PL07784348T
Other languages
English (en)
Inventor
Murat Acemoglu
Joginder S Bajwa
Piotr Karpinski
Dimitris Papoutsakis
Joel Slade
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38564366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2032531(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2032531T3 publication Critical patent/PL2032531T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07784348T 2006-06-12 2007-06-07 Sole N-hydroksy-3-[4-[[[2-(2-metylo-1H-indol-3-ilo)etylo]amino]metylo]fenylo]-2E-2-propenoamidu PL2032531T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US80452306P 2006-06-12 2006-06-12
US86999306P 2006-12-14 2006-12-14
PCT/US2007/070558 WO2007146715A1 (en) 2006-06-12 2007-06-07 Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
EP07784348.0A EP2032531B1 (en) 2006-06-12 2007-06-07 Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide

Publications (1)

Publication Number Publication Date
PL2032531T3 true PL2032531T3 (pl) 2016-07-29

Family

ID=38564366

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07784348T PL2032531T3 (pl) 2006-06-12 2007-06-07 Sole N-hydroksy-3-[4-[[[2-(2-metylo-1H-indol-3-ilo)etylo]amino]metylo]fenylo]-2E-2-propenoamidu

Country Status (38)

Country Link
US (3) US20090197936A1 (pl)
EP (1) EP2032531B1 (pl)
JP (2) JP2009540005A (pl)
KR (2) KR101629352B1 (pl)
AR (1) AR061298A1 (pl)
AU (1) AU2007257962B2 (pl)
BR (1) BRPI0712771A2 (pl)
CA (1) CA2654439C (pl)
CL (1) CL2007001692A1 (pl)
CR (1) CR10439A (pl)
DK (1) DK2032531T3 (pl)
EA (1) EA015212B1 (pl)
EC (1) ECSP088979A (pl)
ES (1) ES2570934T3 (pl)
GE (1) GEP20105125B (pl)
GT (1) GT200800279A (pl)
HK (1) HK1126496A1 (pl)
HN (1) HN2008001859A (pl)
HR (1) HRP20160291T1 (pl)
HU (1) HUE027126T2 (pl)
IL (1) IL195087A (pl)
JO (1) JO3138B1 (pl)
MA (1) MA30563B1 (pl)
ME (1) ME00531B (pl)
MX (1) MX2008015901A (pl)
MY (1) MY147345A (pl)
NO (1) NO341871B1 (pl)
NZ (1) NZ572547A (pl)
PE (1) PE20080937A1 (pl)
PL (1) PL2032531T3 (pl)
RS (1) RS54640B1 (pl)
SI (1) SI2032531T1 (pl)
SM (1) SMP200900002B (pl)
SV (1) SV2008003126A (pl)
TN (1) TNSN08501A1 (pl)
TW (1) TWI409254B (pl)
UY (1) UY30403A1 (pl)
WO (1) WO2007146715A1 (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140142335A (ko) 2006-06-12 2014-12-11 노파르티스 아게 Ｎ-히드록시-3-〔4-〔〔〔2-(2-메틸-1ｈ-인돌-3-일)에틸〕아미노〕메틸〕페닐〕-2ｅ-2-프로펜아미드의 동질이상체
WO2008086330A2 (en) * 2007-01-10 2008-07-17 Novartis Ag Formulations of deacetylase inhibitors
US8003700B2 (en) 2008-04-07 2011-08-23 Mutual Pharamaceutical Company, Inc. Colchicine solid complex; methods of making; and methods of use thereof
US8519002B2 (en) 2008-04-07 2013-08-27 Takeda Pharmaceuticals U.S.A., Inc. Colchicine solid complex; methods of making; and methods of use thereof
UY32297A (es) * 2008-12-22 2010-05-31 Almirall Sa Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
JP5263211B2 (ja) 2010-03-30 2013-08-14 ブラザー工業株式会社 サーバ、プリンタ、及び、サーバのためのコンピュータプログラム
EP2578570A1 (en) 2011-10-07 2013-04-10 Almirall, S.A. Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
EP2641900A1 (en) 2012-03-20 2013-09-25 Almirall, S.A. Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
MA41544A (fr) 2015-02-19 2017-12-26 Novartis Ag Dosages de panobinostat pour le traitement du myélome multiple
WO2017221163A1 (en) * 2016-06-21 2017-12-28 Alembic Pharmaceuticals Limited Novel salts and polymorphic forms of panobinostat

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
JP2007501775A (ja) * 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
US20050228300A1 (en) * 2004-04-07 2005-10-13 Triage Data Networks Cuffless blood-pressure monitor and accompanying wireless mobile device
NZ572744A (en) * 2006-06-12 2011-05-27 Novartis Ag Process for making salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
KR20140142335A (ko) * 2006-06-12 2014-12-11 노파르티스 아게 Ｎ-히드록시-3-〔4-〔〔〔2-(2-메틸-1ｈ-인돌-3-일)에틸〕아미노〕메틸〕페닐〕-2ｅ-2-프로펜아미드의 동질이상체

Also Published As

Publication number Publication date
RS54640B1 (en) 2016-08-31
IL195087A0 (en) 2009-08-03
HUE027126T2 (en) 2016-08-29
SI2032531T1 (sl) 2016-05-31
TW200815343A (en) 2008-04-01
MX2008015901A (es) 2009-01-12
AU2007257962B2 (en) 2011-06-23
UY30403A1 (es) 2008-01-31
JP2013256542A (ja) 2013-12-26
CL2007001692A1 (es) 2008-05-09
JO3138B1 (ar) 2017-09-20
ME00531B (me) 2011-10-10
AU2007257962A1 (en) 2007-12-21
EA200802382A1 (ru) 2009-06-30
PE20080937A1 (es) 2008-08-29
NZ572547A (en) 2011-06-30
EA015212B1 (ru) 2011-06-30
KR20150029765A (ko) 2015-03-18
HRP20160291T1 (hr) 2016-04-22
IL195087A (en) 2012-10-31
JP5771257B2 (ja) 2015-08-26
CA2654439C (en) 2014-08-05
NO20090128L (no) 2009-03-11
HK1126496A1 (zh) 2009-09-04
JP2009540005A (ja) 2009-11-19
KR101629352B1 (ko) 2016-06-13
BRPI0712771A2 (pt) 2012-09-25
MA30563B1 (fr) 2009-07-01
SMAP200900002A (it) 2009-01-14
EP2032531B1 (en) 2016-02-10
SV2008003126A (es) 2011-07-05
CA2654439A1 (en) 2007-12-21
DK2032531T3 (en) 2016-04-11
WO2007146715A1 (en) 2007-12-21
KR20090026281A (ko) 2009-03-12
AR061298A1 (es) 2008-08-20
TNSN08501A1 (en) 2010-04-14
CR10439A (es) 2009-01-15
GT200800279A (es) 2010-06-16
NO341871B1 (no) 2018-02-12
MY147345A (en) 2012-11-30
GEP20105125B (en) 2010-11-25
ES2570934T3 (es) 2016-05-23
US20100286409A1 (en) 2010-11-11
HN2008001859A (es) 2011-07-19
US20090197936A1 (en) 2009-08-06
SMP200900002B (it) 2010-01-19
US20110112308A1 (en) 2011-05-12
ECSP088979A (es) 2009-01-30
TWI409254B (zh) 2013-09-21
EP2032531A1 (en) 2009-03-11

Similar Documents

Publication Publication Date Title
IL195087A0 (en) Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
IL195015A0 (en) Polymorphs of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide
HK1126495A1 (en) Process for making salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3- yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide n--3-[4-[[[2-(2--1h--3-)]]]]-2e-2-
ZA200809651B (en) Process for making salts of N-hydroxy-3[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide
ZA200809383B (en) Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl] amino]methyl]phenyl]-2E-2propenamide
IL233836A0 (en) Method for preparing n-hydroxy-3-[4-[[[2-(2-methyl-h1-indol-3-yl)ethyl]amino]methyl]phenyl]-e2-2-propanamide
ZA200809094B (en) Polymorphs of N-hydroxy-3-[4[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]pheny]-2E-2-propenamide
CY1117493T1 (el) Αλατα του ν-υδροξυ-3-[4-[[[2-(2-μεθυλ-1η-ινδολ-3-υλ)αιθυλ]αμινο]μεθυλο]φαινυλο]-2ε-2-προπεναμιδιου
DOP2008000069A (es) Sales de n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]amino]metil]]fenil]-2e-2-propenamida.